Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2025 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine...
June 16, 2025 07:02 ET | Source: Ocugen

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
June 11, 2025 07:30 ET | Source: Ocugen

Ocugen To Present at BIO International Convention 2025

MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
June 05, 2025 09:00 ET | Source: Doheny Eye Institute

Doheny Eye Institute Welcomes Emma Lessieur-Contreras, MD, PhD, as Principal Investigator

PASADENA, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions for more than 75 years, is adding to its panel of remarkable vision...
June 05, 2025 07:02 ET | Source: Ocugen

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net...
June 05, 2025 04:00 ET | Source: Oculis Holding AG

Oculis Publishes Results of 2025 Annual General Meeting

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on...
June 03, 2025 04:00 ET | Source: Oculis Holding AG

Oculis to Participate in Upcoming June Investor Conferences

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and...
June 02, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic...
May 27, 2025 07:02 ET | Source: Ocugen

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...
May 22, 2025 08:57 ET | Source: Heidelberg Engineering GmbH

NASA Astronauts Warren Hoburg and Tyson Brunstetter to Headline Heidelberg Engineering’s 2025 International SPECTRALIS Symposium

HEIDELBERG, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- Press Release FOR IMMEDIATE RELEASE NASA Astronauts Warren Hoburg and Tyson Brunstetter to Headline Heidelberg Engineering’s 2025...

Next Page keyboard_arrow_right